Partner Investment Management L.P. Has $142,000 Holdings in Accuray Incorporated (ARAY)

Partner Investment Management L.P. cut its stake in Accuray Incorporated (NASDAQ:ARAY) by 25.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,513 shares of the medical equipment provider’s stock after selling 10,755 shares during the quarter. Partner Investment Management L.P.’s holdings in Accuray were worth $142,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Renaissance Technologies LLC grew its stake in shares of Accuray by 8.6% in the 3rd quarter. Renaissance Technologies LLC now owns 5,312,623 shares of the medical equipment provider’s stock valued at $23,907,000 after purchasing an additional 422,023 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Accuray by 1,329.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 324,279 shares of the medical equipment provider’s stock valued at $1,459,000 after purchasing an additional 301,593 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Accuray by 3,259.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,162,567 shares of the medical equipment provider’s stock valued at $9,732,000 after purchasing an additional 2,098,187 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Accuray by 6.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,243,000 shares of the medical equipment provider’s stock valued at $10,094,000 after purchasing an additional 131,283 shares during the last quarter. Finally, Virtu Financial LLC grew its stake in shares of Accuray by 168.4% in the 3rd quarter. Virtu Financial LLC now owns 94,056 shares of the medical equipment provider’s stock valued at $423,000 after purchasing an additional 59,011 shares during the last quarter. 84.28% of the stock is owned by institutional investors.

ARAY has been the topic of several analyst reports. BidaskClub downgraded Accuray from a “sell” rating to a “strong sell” rating in a research note on Friday, August 17th. Citigroup decreased their price target on Accuray from $4.00 to $3.50 and set a “sell” rating on the stock in a research note on Friday, August 17th. Jefferies Financial Group restated a “buy” rating and issued a $6.00 price target on shares of Accuray in a research note on Friday, August 17th. Finally, BTIG Research restated a “hold” rating on shares of Accuray in a research note on Wednesday, August 22nd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $5.63.

In related news, CFO Shigeyuki Hamamatsu sold 8,762 shares of Accuray stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $4.48, for a total value of $39,253.76. Following the sale, the chief financial officer now directly owns 116,238 shares in the company, valued at $520,746.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Joshua Levine purchased 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $118,750.00. Following the completion of the purchase, the chief executive officer now owns 1,356,036 shares of the company’s stock, valued at $6,441,171. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 48,378 shares of company stock worth $218,502. Company insiders own 3.40% of the company’s stock.

Accuray stock opened at $3.97 on Thursday. The company has a current ratio of 1.69, a quick ratio of 0.96 and a debt-to-equity ratio of 2.74. Accuray Incorporated has a 1-year low of $3.20 and a 1-year high of $6.15. The company has a market capitalization of $344.04 million, a P/E ratio of -14.18 and a beta of 1.51.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Tuesday, October 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Accuray had a negative net margin of 5.79% and a negative return on equity of 42.24%. The business had revenue of $95.83 million during the quarter, compared to analysts’ expectations of $95.10 million. During the same quarter last year, the firm earned ($0.11) earnings per share. On average, equities analysts anticipate that Accuray Incorporated will post -0.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2018/12/06/partner-investment-management-l-p-has-142000-holdings-in-accuray-incorporated-aray.html.

Accuray Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Read More: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply